Results 51 to 60 of about 14,439 (224)

Biosimilars – terms of use [PDF]

open access: yesCurrent Medical Research and Opinion, 2015
The impending expiry of the patent on a number of leading biologic drugs has led to a surge in the development of 'biosimilar' or 'follow-on' products. However, in contrast to generic small-molecule medicines, biosimilars are not identical to their reference products.
Declerck, Paul   +2 more
openaire   +4 more sources

Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns

open access: yesJCO Global Oncology, 2021
PURPOSEBreast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]).
Heloísa M. Resende   +7 more
doaj   +1 more source

Ligand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions

open access: yesAngewandte Chemie International Edition, EarlyView.
Multivalent, ligand‐directed molecular beacons enable fluorescence turn‐on detection of cell‐surface receptors in living cells. The probes strongly engage closely spaced membrane receptors and exhibit conformation‐dependent fluorescence enhancement at the cell surface, enabling wash‐free receptor imaging, inhibitor screening, and functional evaluation ...
Noa Oppenheimer‐Low   +11 more
wiley   +1 more source

An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma

open access: yesScientific Reports
This study compared efficacy and safety of lipegfilgrastim with filgrastim in pediatric patients. Children and adolescents receiving chemotherapy (4 cycles) for Ewing sarcoma or rhabdomyosarcoma were randomized 1:1 to lipegfilgrastim (100 µg/kg) once per
Margarita B. Belogurova   +4 more
doaj   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian   +8 more
wiley   +1 more source

Què són els medicaments biosimilars? [PDF]

open access: yes, 2021
Medicaments biosimilars; Medicaments biològics; UtilitzacióMedicamentos biosimilares; Medicamentos biológicos; UtilizaciónBiosimilar medicines; Biological medicines; UseAquest article explica què són els medicaments biosimilars, quins tipus hi ha ...
Grup d'Informació sobre Medicaments Dirigida a la Ciutadania
core  

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia

open access: yesINNOVATIONS in Pharmacy
Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia.
Mohammed Alqahtani   +2 more
doaj   +1 more source

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

open access: yesPLoS ONE, 2017
ObjectivesThis study examined gastroenterologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.MethodsData were taken from the Adelphi ...
Emma Sullivan   +4 more
doaj   +1 more source

Biosimilars in rheumatology

open access: yesPharmacological Research, 2019
Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C.   +2 more
openaire   +3 more sources

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Home - About - Disclaimer - Privacy